Clinical Scorecard: Preventive Use of Tocilizumab to Mitigate Cytokine Release Syndrome (CRS) in Patients Receiving Teclistamab: Insights from a Single-Center Study
At a Glance
Category
Detail
Condition
Relapsed/Refractory Multiple Myeloma (RRMM)
Key Mechanisms
Teclistamab is a bispecific antibody targeting CD3 on T-cells and BCMA on plasma cells; Tocilizumab is an IL-6 receptor antagonist used prophylactically to reduce CRS
Target Population
Heavily pre-treated RRMM patients refractory to IMID, PI, and anti-CD38 monoclonal antibodies
Care Setting
Initially inpatient for step-up dosing; prophylactic tocilizumab may facilitate outpatient administration
Key Highlights
Prophylactic tocilizumab administered 4 hours prior to second step-up dose reduced incidence of all-grade CRS from 73.3% to 26.3%.
Majority of CRS events in prophylactic cohort were grade 1 with reduced severity and shorter duration (median 1 day).
Prophylactic tocilizumab did not increase grade 3/4 neutropenia and maintained comparable overall response rates to pivotal trials.
Guideline-Based Recommendations
Diagnosis
CRS and ICANS graded per ASTCT criteria.
Management
Administer premedications (dexamethasone, diphenhydramine, acetaminophen) 30 minutes prior to teclistamab doses.
Use prophylactic tocilizumab 8 mg/kg IV (max 800 mg) 4 hours before second step-up dose to mitigate CRS.
Manage CRS and ICANS per institutional guidelines; steroids reserved for higher-grade CRS.
Monitoring & Follow-up
Hospitalization recommended for 48 hours after each step-up dose and first full dose per FDA label.
Monitor for onset of CRS typically within 1-6 days, median 2 days after dosing.
Observe for ICANS, especially concurrent with CRS.
Risks
CRS is common with teclistamab (up to 72% in trials), mostly low grade.
Neutropenia is frequent; grade 3/4 neutropenia occurred in 42.1% with prophylactic tocilizumab.
Potential for ICANS, generally low grade and transient.
Patient & Prescribing Data
53 RRMM patients treated at a single center; median age 69 years; all refractory to IMID, PI, and anti-CD38 mAb.
Prophylactic tocilizumab reduced CRS incidence and severity, decreased steroid use, prevented dose delays and hospital readmissions, without compromising teclistamab efficacy.
Clinical Best Practices
Administer prophylactic tocilizumab 4 hours prior to second step-up dose to reduce CRS risk.
Continue standard premedications before each teclistamab dose.
Monitor patients closely for CRS and ICANS using ASTCT criteria.
Consider outpatient teclistamab administration with prophylactic tocilizumab in appropriate patients.
Use steroids judiciously, primarily for grade ≥2 CRS.
by Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
